Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by canadapieton Mar 31, 2021 2:47pm
87 Views
Post# 32915819

RE:RE:RE:RE:RE:RE:IR working hard

RE:RE:RE:RE:RE:RE:IR working hard



ANALIAS00
 - (3/31/2021 2:18:59 PM) 
RE:RE:RE:RE:RE:IR working hard
It is simple Fred. Financing is not responsible for sales increase, not responsible for Phase I and Phase III go, not responsible for FDA fast track designation... All that was well known by TH and anybody could anticipate an increase in the SP since every indications were green. SP could only be increasing with all the known indicators. Financing DID dilute a lot the stock but you seem not to understand what dilution is. As long as you can do a buck you are happy even if could have made 3. I think we all agree that dilution was necessary, TH eventually needed cash. They just did not manage to sign a GOOD deal for them and for us old shareholders. We said it many time, the timing was bad. Dont you understand that the new investors got the stock for almost nothing. I strongly beleive the SP would be at >6$ with a better timing and condition of the financing. I am still making a buck and I might do more ... But that is not just the way to look at it. Do they deserve positive recognition for all work done during the last year ? Of course they do. But they clearly failed on the financing aspect and everyone should recognize that. They would have been genius only if they had no hope on their future. The thing is they are full of hope in their pipeline and in their sales to come. Financing DID NOT CAUSE the SP to increase. 
FredTheVoice wrote:"Mr Market got screwed by the Financing but the recovery is on the way" - Palinc

Wonder How PALINC comes to that conclusion when ...since the financing the stock price is going up !!!!

And how can we be sure that the share price, without financing, would be higher ???? Hello Nostradamus !!!

Im with JFM on that one !

FTV.
 
Let us be honest and correct : the "financing" was a terrible and horrible thing for the shareholders that never should have happened!!! But we are where we are. 
If an investor was doing his DD (and we all did.....), the dilution could have been foreseen, but not at those "terms"!
But a few days thereafter, one could buy the share for far less then the dilution price! So we had all our moment to build up our position. 
It is clear that in comparison to other biotechs, TH is far "underpriced" NOW, so if they (Mr. Levesque) can execute on our 2 products AND  oncology or Nash shows early promising results..........

Good luck all, but foremost stay healthy!!!! 

Ps: In Oncology, maybe a good bet could be ONCT
<< Previous
Bullboard Posts
Next >>